thinkpool

 In today's press release about a conference presentation announcement, I read through the verbiage and came to this section "Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus

콘퍼런스 프레젠테이션 발표에 대한 오늘 보도자료에서, 저는 의견을 읽었고, 이 섹션에 왔습니다. "휴머니겐은 COVID-19 및 CD19 표적 CAR-T 세포 치료제와 관련된 사이토카인 폭풍 치료제로 렌질루맙을 개발하고 있으며, 또한 그러한 염증 조건에서 렌질루맙의 효과를 조사하고 있습니다. 급성 이식 대

The FDA granted approval of Orencia to Bristol Myers Squibb.

Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD)

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-prevent-graft-versus-host-disease

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

https://www.prnewswire.com/news-releases/nuvation-bio-receives-fda-fast-track-designation-for-nuv-422-for-the-treatment-of-high-grade-gliomas-including-glioblastoma-multiforme-301444794.html

FDA는 브리스톨 마이어스 스퀴브에게 오렌시아를 승인했다.

오늘 미국 식품의약국은 오렌시아(아바타셉트)를 급성 이식 대 숙주 질병(aGVHD)의 예방에 대해 승인했다.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-prevent-graft-versus-host-disease

Nuation Bio, 교모세포종 다형종을 포함한 고급 교모종 치료를 위해 FDA Fast Track 지정을 받다

https://www.prnewswire.com/news-releases/nuvation-bio-receives-fda-fast-track-designation-for-nuv-422-for-the-treatment-of-high-grade-gliomas-including-glioblastoma-multiforme-301444794.html